Avalo Therapeutics Inc (NASDAQ: AVTX) stock enjoyed a major increase of 13.6% on 10/24/24. The shares closed at $13.20. Moreover, trading volume in this advance was exceptionally high at 498% of normal. Relative to the market the stock has been exceptionally strong over the last nine months and has risen 28.3% during the last week.
Current PriceTarget Research Rating
AVTX’s future returns on capital are forecasted to fall short of the cost of capital. Accordingly, the company is expected to continue to be a modest Value Eraser.
Avalo Therapeutics has a current Value Trend Rating of C (Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Avalo Therapeutics has a poor Appreciation Score of 20 but a very high Power Rating of 92, resulting in the Neutral Value Trend Rating.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment